John M. Errico

Vir Biotechnology (Switzerland) — Switzerland

Medicine · Health Sciences

21h-index4.0kcitations34works13.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(18), Mosquito-borne diseases and control(8), Viral gastroenteritis research and epidemiology(8), SARS-CoV-2 detection and testing(7), COVID-19 Clinical Research Studies(6)

Publications34 total

Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells
Journal of Hepatology·2025· 4 cited
Potent efficacy of a NA-targeting antibody against a broad spectrum of H5N1 influenza viruses
2025Open Access
The engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor positive cells leading to activation of HBV-specific T cells
2025Open Access
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Cell·2024· 51 citedOpen Access
Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8
Cell·2023· 36 citedOpen Access
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
Nature Communications·2022· 151 citedOpen Access
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
2022· 37 citedOpen Access
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Nature Medicine·2022· 758 citedOpen Access
Antibody-mediated immunity to SARS-CoV-2 spike
Advances in immunology·2022· 25 citedOpen Access
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
2021· 81 citedOpen Access
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
2021· 26 citedOpen Access
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity
Cell Host & Microbe·2021· 15 citedOpen Access
Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
Cell Reports·2021· 25 citedOpen Access
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Nature·2021· 260 citedOpen Access
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
2021· 31 citedOpen Access
Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses
The Journal of Experimental Medicine·2021· 30 citedOpen Access
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Nature Medicine·2021· 1.0k citedOpen Access
On the road to ending the COVID-19 pandemic: Are we there yet?
Virology·2021· 53 citedOpen Access
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
2021· 88 citedOpen Access
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Cell Host & Microbe·2021· 841 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Daved H. Fremont(26), Michael Diamond(17), Laura A. VanBlargan(15), Davide Corti(11), James E. Crowe(10), Rita E. Chen(8), James Brett Case(8), Lisa A. Purcell(8), Ali H. Ellebedy(7), Zhuoming Liu(7), Sean P. J. Whelan(7), Emma S. Winkler(6), Seth J. Zost(6), Lindsay Droit(6), Haiyan Zhao(6), Scott A. Handley(6), Christopher A. Nelson(6), David Wang(5), Pei‐Yong Shi(5), Spencer Stumpf(5)